Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007559 | 0.84 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPTPNPXDH | |
| SCHEMBL4008262 | 0.82 | MAPT (0.55) | SMN1; SMN2MAPTLMNAKDM4EPNP | |
| SCHEMBL19233117 | 0.72 | MAPT (0.59) | SMN1; SMN2MAPTKDM4EMEN1KMT2A | |
| SCHEMBL8972962 | 0.70 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL5383067 | 0.69 | MEN1 (0.50) | SMN1; SMN2MAPTLMNAKDM4EMEN1 | |
| SCHEMBL15844018 | 0.68 | DAO (0.54) | SMN1; SMN2MAPTLMNAKDM4EPNP | |
| SCHEMBL4007561 | 0.68 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTLMNAKDM4EPNP | |
| SCHEMBL14361658 | 0.67 | MAPT (0.63) | SMN1; SMN2MAPTKDM4EMEN1KMT2A | |
| SCHEMBL7974083 | 0.67 | ACP1 (0.43) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| SCHEMBL8973406 | 0.66 | L3MBTL1 (0.40) | SMN1; SMN2MAPTLMNAKDM4EPNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483247-B1 | ARYL SUBSTITUTED PYRIMIDINES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2009-06-24 | — | — | EP | claimed |
| US-7229993-B2 | Aryl substituted pyrimidines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-06-12 | — | — | US | claimed |
| EP-1483247-A2 | ARYL SUBSTITUTED PYRIMIDINES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2004-12-08 | — | — | EP | claimed |
| US-20030236273-A1 | Aryl substituted pyrimidines and the use thereof | EURO-CELTIQUE S.A. | 2003-12-25 | — | — | US | claimed |
| WO-2003076414-A2 | ARYL SUBSTITUTED PYRIMIDINES AND THE USE THEREOF | EURO-CELTIQUE S.A. (US) | 2003-09-18 | — | — | WO | claimed |
| EP-1483247-B1 | ARYL SUBSTITUTED PYRIMIDINES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2009-06-24 | — | — | EP | disclosed |
| US-7229993-B2 | Aryl substituted pyrimidines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-06-12 | — | — | US | disclosed |
| EP-1483247-A2 | ARYL SUBSTITUTED PYRIMIDINES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2004-12-08 | — | — | EP | disclosed |
| US-20030236273-A1 | Aryl substituted pyrimidines and the use thereof | EURO-CELTIQUE S.A. | 2003-12-25 | — | — | US | disclosed |
| WO-2003076414-A2 | ARYL SUBSTITUTED PYRIMIDINES AND THE USE THEREOF | EURO-CELTIQUE S.A. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236273-A1 | Aryl substituted pyrimidines and the use thereof | CACNA1S, CACNA1C, NCS1 | SMN1; SMN2 21/4885MAPT 450/4885LMNA 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.